痴呆养老院住民口服双膦酸盐deprescribing模式
该研究基于2015-2016年美国国家医保数据,分析痴呆养老院住民口服双膦酸盐的deprescribing(停药)发生率及相关因素。使用90天药物供应缺口定义时,180天累积停药发生率为14.8%;高龄、新入住、行动依赖、吞咽困难、既往多次住院等与更高停药可能性相关。
要点
- 痴呆养老院住民双膦酸盐停药不常见,90天缺口定义下180天累积发生率为14.8%。
- 高龄≥90岁、行动依赖、吞咽困难、既往住院>1次等与更高停药可能性相关。
- 癌症及西部地理区域与更低停药可能性相关。
核心结论
- 在痴呆养老院住民中,双膦酸盐deprescribing不常见,且与提示预后差和长期获益可能性低的临床特征相关。
研究设计与样本
- 基于2015-2016年Medicare理赔数据、Part D处方、MDS 3.0及Nursing Home Compare,纳入65岁以上非专业养老院痴呆住民,其口服双膦酸盐处方覆盖入住前14天。
- 采用竞争风险回归模型估计养老院、提供者及住民特征与双膦酸盐deprescribing的关联。
主要发现
- 共纳入5312名接受双膦酸盐治疗的痴呆养老院住民,其中72%≥80岁,81%为白人,90%为女性;约50%转移依赖,45%行动依赖。
- 使用90天供应缺口定义时,180天累积deprescribing发生率为14.8%;使用30天缺口为32.1%,使用180天缺口为11.7%。
- 与停药可能性增加相关的因素包括:年龄≥90岁、新入住(相对于长期住民)、行动依赖、吞咽困难、既往一年内住院>1次、CCRC机构、执业护士作为主要提供者(相对于医生)。
- 癌症及西部地理区域与停药可能性降低相关。
关键数值与推荐
- 主要deprescribing定义为90天药物供应缺口;同时探索了30天、90天、180天缺口的可靠性。
- 90天缺口定义下180天累积deprescribing发生率为14.8%。
临床怎么用
- 对痴呆养老院住民处方双膦酸盐时,可结合高龄、行动依赖、吞咽困难、近期多次住院等特征评估长期获益可能性,个体化考虑deprescribing。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: In a national sample of Medicare nursing home residents with dementia treated with bisphosphonates, 20% had bisphosphonates deprescribed. Residents with clinical characteristics representing decreased likelihood for long-term benefit were more likely to have bisphosphonates deprescribed. Future studies are needed to evaluate outcomes of deprescribing bisphosphonates in this population. INTRODUCTION: To determine incidence of deprescribing bisphosphonates among nursing home (NH) residents with dementia and identify factors associated with deprescribing. METHODS: 2015-2016 Medicare claims, Part D prescriptions, Minimum Data Set (MDS) 3.0, and Nursing Home Compare for non-skilled NH residents aged 65 + with dementia and prescriptions for oral bisphosphonates overlapping the first 14 days of the stay. Our primary definition for deprescribing was a 90-day gap in medication supply; we also explored the reliability of different deprescribing definitions (30-, 90-, 180-day gaps). We estimated associations of NH, provider, and resident characteristics with deprescribing bisphosphonates using competing risks regression models. RESULTS: Most NH residents with dementia treated with bisphosphonates (n = 5312) were ≥ 80 years old (72%), white (81%), and female (90%); about half were dependent for transfers (50%) or mobility (45%). Using a 90-day gap in supply, the 180-day cumulative incidence of deprescribing bisphosphonates was 14.8%. This increased to 32.1% using a 30-day gap and decreased to 11.7% using a 180-day gap. Factors associated with increased likelihood for bisphosphonate deprescribing were age ≥ 90 years, newly admitted (vs. prevalent stay), dependent for mobility, swallowing difficulty, > 1 hospitalization in the prior year, CCRC facility, and nurse practitioner primary provider (vs. physician). Cancer and western geographic region were associated with reduced likelihood for deprescribing. CONCLUSION: In a national sample of NH residents with dementia, bisphosphonate deprescribing was uncommon, and associated with clinical characteristics signifying poor prognosis and decreased likelihood for long-term benefit. Future studies should evaluate clinical outcomes of deprescribing bisphosphonates in this population.
引用
- Niznik JD, Aspinall SL, Hanson LC, et al. Patterns of oral bisphosphonate deprescribing in older nursing home residents with dementia. Osteoporos Int. 2021. PMID: 34480586. doi:10.1007/s00198-021-06141-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。